Clinical quality management system

Clinical Quality Management Systems ( CQMS ) are used in the life sciences sector (in the pharmaceutical, biological and medical device industries). A CQMS system is designed to manage all the documents, activities, tasks, processes, quality events, relationships, audits and training that must be administered and controlled throughout the life of a clinical trial. The Clinical Quality and Clinical Operations, Clinical Quality and Clinical Operations,

Based on the principles of quality management systems (QMS), which are used in many industries to create a framework for defining and delivering quality outcomes, managing risk , and continual improvement . Many guidelines and governance bodies have been established to ensure a common approach within a given industry. The pharmaceutical industry is no exception, with several trade groups (eg PhRMA, EFPIA, RQA, etc.) coming together to enhance collaboration. However, as noted by the Academy of Medical Sciences, there are increasingly complex and bureaucratic legal and ethical frameworks that innovators must work within to develop new medicines for patients. [1]

The historical pharmaceutical QMS. International Organization for Standardization and ICH (International Committee on Harmonization) guidelines. “Good Manufacturing Practices (GMP),” which is the first of its kind in the United States. Even dangerous. ” [2]

These standards have historically been applied to the manufacturing environment. [3] Implantation of ICH Q10 and the FDA in the United States of America. Research space, in the lifecycle of an investigational or marketed product. Accordingly, a CQMS is any system developed to apply these principles to clinical operations within an organization.


  1. Jump up^ “Strengthening clinical research (Report of an Academy working group)” (PDF) . Academy of Medical Sciences . London. 2003. ISBN  1-903401-05-4 . Retrieved 2016-12-16 .
  2. Jump up^ “ISO gives pharmaceutical industry new management tool to improve patient safety” . .
  3. Jump up^ Moheb M. Nasr, Ph.D., Office of New Drug Quality Assessment, OPS / CDER / FDA (July 27, 2011). Transcript of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology .

Leave a Comment

Your email address will not be published. Required fields are marked *